aTyr Pharma, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- aTyr Pharma, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of innovative medicines based on novel biology, specifically leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company’s core products include a proprietary pipeline of protein compositions derived from 20 tRNA synthetase genes, with a primary focus on efzofitimod (ATYR1923), a first-in-class biologic immunomodulator designed to bind the neuropilin-2 receptor. Efzofitimod targets severe inflammatory lung diseases and interstitial lung disease (ILD), a group of immune-mediated disorders characterized by chronic inflammation and progressive fibrosis of the lungs. In addition to efzofitimod, aTyr Pharma is advancing therapeutic candidates such as ATYR0101, which has moved to IND candidate status for pulmonary fibrosis, and other antibody-based therapies targeting neurological and oncological conditions. Founded in 2008 and headquartered in San Diego, California, aTyr Pharma operates globally, with clinical trial sites spread across the United States, Europe, Japan, and Brazil. The company has established strategic partnerships, including a license agreement with Kyorin Pharmaceutical Co., Ltd. for development and commercialization of efzofitimod in Japan. aTyr’s pipeline focuses on high unmet medical needs such as pulmonary sarcoidosis, systemic sclerosis-related ILD, and fibrotic diseases, deploying its unique platform that uncovers hidden therapeutic intervention points by exploiting extracellular signaling pathways regulated by tRNA synthetases. Significant recent developments for the company include the completion of patient enrollment and last patient visit in its pivotal Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, which enrolled 268 patients across 85 centers in nine countries with topline results anticipated by mid-September 2025. The Phase 2 EFZO-CONNECT™ study targeting systemic sclerosis-associated ILD is ongoing with promising interim data showing improvements in skin fibrosis and relevant biomarkers. Furthermore, aTyr Pharma reported $92.9 million in cash and investments as of September 30, 2025, demonstrating solid financial positioning to support its clinical programs. The company plans to meet with the U.S. FDA in the first quarter of 2026 to discuss regulatory pathways following the EFZO-FIT results. aTyr continues to focus on expanding its therapeutic pipeline, advancing antibody candidates like ATYR2810, targeting neuropilin-2 in cancer, and strengthening its intellectual property portfolio based on its tRNA synthetase platform.
Company News
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1% – Should You Sell?
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit